ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Teladoc (TDOC) stock price analysis and the fall from grace

By: Invezz
cathie wood buys more of Teladoc stock

Teladoc (NYSE: TDOC) stock price has been one of the worst performers in Wall Street in the past few years. It peaked at $307 in 2021 as most Americans embraced telehealth services. 

Today, the stock has collapsed to just $13, a move that has cost its investors billions of dollars. If you invested $10,000 in the company at its peak, you would now have less than $500. Its market cap has fallen from over $46 billion to about $2.3 billion.

Teladoc Health earnings ahead

Teladoc Health has had a remarkable fall from grace as demand for the telehealth industry has fizzled after the COVID-19 pandemic. 

The company made a few mistakes in its happier times. Its biggest one was to acquire Livongo Health, another telehealth company in a deal valued at over $18 billion. 

The merger was ill-timed, which pushed its business to a net loss of over $13 billion in 2022 as it wrote down its valuation. 

Its growth trajectory has fizzled and this trend may continue in the coming years. The most recent results revealed that Teladoc Health’s revenue rose by 4% in the fourth quarter and by 8% in 2023. It made $660 million in the quarter and delivered a net loss of over $28 million. 

I believe that the company’s business will continue facing challenges in the next few years as the number of people seeking telehealth services fall. This explains why UnitedHealth, the biggest insurer in the US, has decided to wind down Optum’s telehealth business. 

Most importantly, BetterHelp, its online therapy solution is also not growing. Its revenue in the fourth quarter was $276 million, down from $277 million in the same quarter a year earlier.

Looking ahead, the company is set to publish its financial results on Thursday. In its last quarter’s financial release, the company’s revenue moved to between $630 million and $645 million. It expects that its net loss per share will be between 55 and 45 cents. 

The average estimate by 25 analysts tracking the company is that its revenue will come in at $637 million this quarter followed by $662 million in Q2. Most of these analysts have a hold rating on the company with an average stock estimate of $19.55, higher than the current $13.73.

Teladoc stock price forecastTeladoc stock

TDOC chart by TradingView

It is always difficult to predict a stock’s performance before earnings. For example, Teladoc’s stock crashed hard after publishing its last two financial results. But it also jumped by over 30% when it released its numbers in July last year.

Turning to the daily chart, we see that the TDOC stock price has collapsed hard in the past few monthS. It crashed below the important support at $15, its lowest point on October 30th. 

The stock has remained below all moving averages and the Ichimoku cloud indicator. The Relative Strength Index (RSI) has pointed upwards and is nearing the neutral point of 50. 

Therefore, the outlook for the stock is neutral, with the key support and resistance levels to watch being at $12.82 and $15.05. 

The post Teladoc (TDOC) stock price analysis and the fall from grace appeared first on Invezz

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.